Wearable medical device company Kestra (KMTS.US) applies for IPO in the US, intending to raise 100 million US dollars.

Wearable medical device company Kestra Medical Technologies has filed for an initial public offering (IPO), planning to raise $100 million. The pricing terms of its IPO have not been disclosed. The company plans to list on the Nasdaq under the stock code "KMTS". Information shows that Kestra is a company that produces wearable cardioverter defibrillators for high-risk cardiac arrest patients. Its wearable cardioverter defibrillator system ASSURE WCD represents the next generation of technology for cardiac monitoring and defibrillation therapy, providing various functions including automatic detection and defibrillation, analyzing heart rhythms, providing defibrillation therapy, and being compatible with remote patient data platforms, and has been approved by the US Food and Drug Administration (FDA). Data shows that as of January 31, 2025, Kestra's wearable cardioverter defibrillator system has been actively used by over 550 hospitals in the United States (approximately 20% of hospitals prescribing WCDs in the US); since its full commercial launch in August 2022, it has been used by over 17,000 patients. In addition, the company's sales revenue for the 12 months ending October 31, 2024 was $46 million. Kestra's investors include Bain Capital LP and Endeavour Vision. The company raised $196 million in a funding round in July last year, led by Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds.